SCHEMBL6489563

SCHEMBL6489563

Cc1cc(-c2cccc(C(=O)O)c2)cc2c1nc(C)n2Cc1ccccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
ALOX5AP P20292 3/20 0.51
PIK3C2B O00750 3/20 0.47
PPARG P37231 2/20 0.44
TSHR P16473 1/20 0.44
PTGES O14684 1/20 0.43
ALOX5 P09917 1/20 0.43
LTC4S Q16873 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
DCTPP1 Q9H773 2/20 0.43
PIK3CB P42338 2/20 0.42
CCR2 P41597 1/20 0.42
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6496733 0.92 ALOX5AP (0.47) SMN1; SMN2NPC1RAB9ACASP3SENP8
SCHEMBL6490645 0.90 PTGDR (0.44) SMN1; SMN2NPC1RAB9ACASP3SENP8
SCHEMBL6487982 0.86 DCTPP1 (0.41) SMN1; SMN2NPC1RAB9ACASP3SENP8
SCHEMBL6488966 0.85 RXRA (0.41) SMN1; SMN2NPC1RAB9ACASP3SENP8
SCHEMBL6497678 0.83 PTPN11 (0.46) PPARG
SCHEMBL6487328 0.83 RXRA (0.40) PPARGDCTPP1RXRARXRB
SCHEMBL6490261 0.82 CYP1A2 (0.42) SMN1; SMN2RAB9AALOX5AP
SCHEMBL6498502 0.82 ALOX5AP (0.37) SMN1; SMN2NPC1RAB9ACASP3SENP8
SCHEMBL6486764 0.82 DCTPP1 (0.44) ALOX5APPIK3C2BPPARGPTGESALOX5
SCHEMBL6923139 0.81 ALDH1A1 (0.38) SMN1; SMN2NPC1RAB9ACASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD SMN1; SMN2 1128/4885NPC1 315/4885RAB9A 2599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.